{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["148(2)"],"submitter":["Ocal O"],"funding":["Sirtex","Bayer HealthCare","Ludwig-Maximilians-Universität München"],"pubmed_abstract":["<h4>Purpose</h4>To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.<h4>Methods</h4>A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response.<h4>Results</h4>Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and "],"journal":["Journal of cancer research and clinical oncology"],"pagination":["475-485"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8800931"],"repository":["biostudies-literature"],"pubmed_title":["Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial."],"pmcid":["PMC8800931"],"pubmed_authors":["Ocal O","Ben Khaled N","Ricke J","Wildgruber M","Pech M","Berg T","Benckert J","Morkunas E","Basu B","Sangro B","Sengel C","Seidensticker M","Gasbarrini A","Klumpen HJ","Palmer D","Kupcinskas J","Malfertheiner P","de Toni EN","Jurkeviciute G","Valle JW","Seidensticker R","Schutte K"],"additional_accession":[]},"is_claimable":false,"name":"Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.","description":"<h4>Purpose</h4>To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.<h4>Methods</h4>A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response.<h4>Results</h4>Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-09T20:21:08.956Z","creation":"2022-02-11T15:37:30.549Z"},"accession":"S-EPMC8800931","cross_references":{"pubmed":["33855585"],"doi":["10.1007/s00432-021-03627-1"]}}